Company* (Country; Symbol) |
Company* (Country; Symbol) |
Product |
Terms/Details (Date) |
| |||
Agencourt Biosciences Corp.* |
Integrated Genomics Inc.* |
A suite of library construction, sequencing and bioinformatics services |
Companies will co-market the services; Agencourt will provide library construction and high-throughput sequencing through its Discovery Solutions suite of genomic services; Integrated Genomics will expand Agencourt's existing genome assembly capabilities with downstream genetic analysis software, bioinformatics services and a genome database (8/20) |
|
|||
Cambrex Bio Science Verviers Sprl (subsidiary of Cambrex Corp.; NYSE:CBM) |
Clinical Cell Culture Ltd. (Australia; ASX:CCE) |
CellSpray and CellSpray XP |
Cambrex will become the European manufacturer of Clinical Cell's products (9/10) |
|
|||
Epoch Biosciences Inc. (EBIO) |
Applied Biosystems Group (NYSE:ABI) |
Eclipse Dark Quencher technology |
Applied Biosystems gained a license to manunfacture, sell and distribute TaqMan probes that carry the quencher technology; Epoch will receive license fees and royalties on Applied Biosystems' sales to purchasers of licensed products (9/17) |
|
|||
Hemispherx Biopharma Inc. (AMEX:HEB) |
Engitech Inc.* |
Alferon N |
Sales and Marketing agreement for Engitech to launch Alferon N on a nationwide scale (8/18) |
|
|||
ICOS Corp. (ICOS) |
Protein Design Labs Inc. (PDLI) |
M200 antibody |
ICOS will manufacture the product for Phase I trials; financial terms were not disclosed (10/9) |
|
|||
MultiCell Technologies Inc. (subsidiary of Exten Industries Inc.; EXTI) |
XenoTech LLC* |
MultiCell's liver cell lines |
XenoTech gains a seven-year exclusive right to distribute globally the cell lines in exchange for $1.5M up front (8/20) |
|
|||
PamGene International BV* (the Netherlands) |
Linden Bioscience* (division of Linden Technologies Inc.) |
Tilia Oligonucleotide Probe Design Service |
PamGene will have access to Linden's service; oligonucleotide probes are used in the manufacture of DNA microarrays for gene expression applications (9/8) |
|
|||
Prima Biomed Ltd. (Australia; ASX:PRR) |
Progen Industries Ltd. (Australia; PGLAF) |
Therapeutic vaccine |
Prima will begin scale-up manufacture of the vaccine for Phase II trials; financial terms were not disclosed (10/8) |
|
|||
StemCells Inc. (STEM) |
StemCell Technologies Inc.* (Canada) |
StemCells' mouse and rat neural stem cells and culture media for all mammalian neural stem cells |
StemCell Technologies will manufacture, use and sell certain of StemCells' stem cells for educational and research purposes worldwide (9/17) |
|
|||
|
|||
Notes: | |||
# The information in the chart does not cover agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; ASX = Australia Stock Exchange; NYSE = New York Stock Exchange. |